Entropy Technologies LP Buys Shares of 20,197 Natera, Inc. $NTRA

Entropy Technologies LP acquired a new position in Natera, Inc. (NASDAQ:NTRA) during the 4th quarter, HoldingsChannel.com reports. The firm acquired 20,197 shares of the medical research company’s stock, valued at approximately $4,627,000.

Several other large investors have also recently made changes to their positions in the stock. Horizon Investments LLC lifted its holdings in shares of Natera by 22.0% in the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after acquiring an additional 44 shares during the last quarter. Sound Income Strategies LLC lifted its holdings in Natera by 20.0% during the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after buying an additional 45 shares in the last quarter. Savvy Advisors Inc. lifted its holdings in Natera by 3.1% during the 4th quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock worth $353,000 after buying an additional 46 shares in the last quarter. Siemens Fonds Invest GmbH lifted its holdings in Natera by 3.1% during the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock worth $290,000 after buying an additional 54 shares in the last quarter. Finally, Alamea Verwaltungs GmbH lifted its holdings in Natera by 2.9% during the 4th quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company’s stock worth $515,000 after buying an additional 62 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Stock Performance

Shares of NASDAQ:NTRA opened at $212.07 on Monday. Natera, Inc. has a 52 week low of $131.81 and a 52 week high of $256.36. The company’s 50 day moving average is $206.49 and its two-hundred day moving average is $215.83. The company has a market cap of $30.37 billion, a PE ratio of -130.10 and a beta of 1.56.

Analyst Upgrades and Downgrades

NTRA has been the topic of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a report on Tuesday, April 21st. Robert W. Baird set a $265.00 target price on shares of Natera in a report on Friday, May 8th. Evercore reiterated an “outperform” rating and set a $270.00 target price on shares of Natera in a report on Friday, May 8th. BTIG Research reduced their target price on shares of Natera from $260.00 to $250.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Finally, Wall Street Zen lowered shares of Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and an average price target of $256.53.

Insider Buying and Selling

In other Natera news, insider John Fesko sold 1,438 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $202.84, for a total value of $291,683.92. Following the sale, the insider directly owned 185,782 shares of the company’s stock, valued at approximately $37,684,020.88. This represents a 0.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Gail Boxer Marcus sold 11,000 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the completion of the sale, the director directly owned 6,183 shares in the company, valued at approximately $1,343,009.43. This represents a 64.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 159,378 shares of company stock worth $34,640,860. Corporate insiders own 5.05% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.